ArticleAmyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis2020
Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis.
Article in Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Minimal residual disease in systemic light chain amyloidosis: a systematic review and meta-analysis.Journal of cancer research and clinical oncology · 2024Pooled it
- Detection of minimal residual disease by next generation sequencing in AL amyloidosis.Blood cancer journal · 2021Trial
- Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis.Blood advances · 2020Trial
- A Multicenter National Study of AL Amyloidosis in China: Insights Into Real-World Diagnosis, Treatment, and Prognosis.American journal of hematology · 2026Article
- Proving Bone Marrow Plasma Cell Clonality by Flow Cytometry: An Important Tool in the Diagnosis of Immunoglobulin Light-Chain Amyloidosis.Biomedicines · 2025Article
- Early minimal residual disease eradication in light chain amyloidosis generates deeper and faster cardiac response.Clinical and experimental medicine · 2024Article
- Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
- Immunoglobulin Light Chain Amyloidosis: Diagnosis and Risk Assessment.Journal of the National Comprehensive Cancer Network : JNCCN · 2023Review
- Bad players in AL amyloidosis in the current era of treatment.Expert review of hematology · 2023Article
- Clinical value of minimal residual disease assessed by multiparameter flow cytometry in amyloid light chain amyloidosis.Journal of cancer research and clinical oncology · 2022Article
- Light Chain Amyloidosis: Epidemiology, Staging, and Prognostication.Methodist DeBakey cardiovascular journal · 2022Review
- Article
- Biomarkers in AL Amyloidosis.International journal of molecular sciences · 2021Review
- Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis.Blood cancer journal · 2021Article
- Future Perspectives.Hematology/oncology clinics of North America · 2020Review
- Updates in the Diagnosis and Management of AL Amyloidosis.Current hematologic malignancy reports · 2020Review
- Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis.American journal of hematology · 2020Article
- Systemic amyloid light-chain amyloidosis beyond ANDROMEDA: Diagnostic challenges and therapeutic updates.CA: a cancer journal for cliniciansReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 2 institutions in 1 country.
Funding
Abstract
Response assessment in light chain (AL) amyloidosis is challenging given the low level of circulating free light chains usually seen. Multi-parametric flow cytometry (MFC) from a marrow aspirate was demonstrated to retain a prognostic significance in several recent studies. In this work, 82 AL patients who had MFC study at end of therapy were analysed based on whether clonal plasma cells were detected or not. Among patients who achieved deep response (i.e. very good partial response or complete response) to first-line therapy, lack of clonal marrow plasma cells as measured by MFC was associated with improved progression-free survival (PFS) compared to patients with residual clonal plasma cells (3-year PFS 88% vs. 46%,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.